Search - tctmd.com

Displaying 381 - 400 of 4894

Sort: Relevancy | Date

News Daily News

Private Equity Firms Own Half of Cardiology Practices: MedAxiom Survey

Todd Neale

November 12, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Daily News

IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC

Michael O'Riordan

November 11, 2024

News Daily News

Coronary CTA Reimbursement for US Hospitals to Double in 2025

Yael L. Maxwell

November 08, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Conference News VIVA 2024

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

L.A. McKeown

November 07, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Daily News

Machismo in Youth Linked to Fewer CVD Diagnoses, Less Treatment in Adulthood

Caitlin E. Cox

November 06, 2024

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2024

Shelley Wood

November 01, 2024

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Advertisement

Private Equity Firms Own Half of Cardiology Practices: MedAxiom Survey

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC

Coronary CTA Reimbursement for US Hospitals to Double in 2025

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Advocates Urge Heat Maps and Grassroots Campaigns to Improve PAD Care

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Machismo in Youth Linked to Fewer CVD Diagnoses, Less Treatment in Adulthood

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

TCTMD’s Top 10 Most Popular Stories for October 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content